Table 2 Changes from baseline to week 24 in NT-proBNP concentration
NT-proBNP, pg/mL | Canagliflozin | Glimepiride |
|---|---|---|
All patients | (n = 101) | (n = 109) |
 Baseline | 230.6 (178.2 to 298.3) | 205.3 (160.2 to 263.0) |
 Week 24 | 225.2 (174.1 to 291.3) | 219.5 (171.3 to 281.2) |
 Proportional change from baseline to week 24 | 0.98 (0.89 to 1.08) | 1.07 (0.97 to 1.18) |
Naïve | (n = 36) | (n = 42) |
 Baseline | 302.4 (206.7 to 442.5) | 309.1 (217.3 to 439.6) |
 Week 24 | 277.3 (189.5 to 405.7) | 298.9 (210.1 to 425.2) |
 Proportional change from baseline to week 24 | 0.92 (0.78 to 1.08) | 0.97 (0.83 to 1.12) |
Non-naïve | (n = 65) | (n = 67) |
 Baseline | 198.4 (141.9 to 277.4) | 158.8 (114.2 to 220.9) |
 Week 24 | 200.6 (143.5 to 280.5) | 180.9 (130.1 to 251.6) |
 Proportional change from baseline to week 24 | 1.01 (0.89 to 1.14) | 1.14 (1.01 to 1.29) |
Non-naïve metformin user | (n = 15) | (n = 24) |
 Baseline | 148.6 (67.2 to 328.6) | 124.9 (66.7 to 233.9) |
 Week 24 | 167.3 (75.7 to 370.1) | 158.3 (84.5 to 296.4) |
 Proportional change from baseline to week 24 | 1.13 (0.89 to 1.42) | 1.27 (1.05 to 1.53) |
Non-naïve DPP-4 inhibitor user | (n = 57) | (n = 57) |
 Baseline | 213.9 (149.3 to 306.4) | 164.0 (114.5 to 235.0) |
 Week 24 | 207.7 (145.0 to 297.5) | 181.9 (127.0 to 260.5) |
 Proportional change from baseline to week 24 | 0.97 (0.85 to 1.11) | 1.11 (0.97 to 1.26) |